Get the Stockscreener App
17.68
0.31%
-0.065
Roivant Sciences Ltd stock is traded at $17.68, with a volume of 2.78M.
It is down -0.31% in the last 24 hours and up +17.59% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$17.74
Open:
$17.65
24h Volume:
2.78M
Relative Volume:
0.42
Market Cap:
$12.08B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
3.1283
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
+7.84%
1M Performance:
+17.59%
6M Performance:
+76.15%
1Y Performance:
+52.19%
1-Day Range:
$17.54
$17.93
1-Week Range:
$16.41
$18.06
52-Week Range:
$8.73
$18.06
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
17.70 | 12.11B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.62 | 107.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
476.58 | 64.39B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
579.21 | 61.13B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.51 | 52.30B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
317.78 | 34.99B | 4.56B | -176.77M | 225.30M | -1.7177 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) - Insider Monkey
13 Best Growth Stocks Under $25 to Buy Right Now - Insider Monkey
Risk vs reward if holding onto Roivant Sciences Ltd.Wall Street Watch & Accurate Entry/Exit Alerts - newser.com
Chart based exit strategy for Roivant Sciences Ltd.Weekly Trading Summary & Weekly Stock Breakout Alerts - newser.com
Roivant Sciences Ltd. stock prediction for this weekMarket Performance Report & Weekly Stock Performance Updates - newser.com
Is Roivant Sciences Ltd. (87S) stock undervalued historicallyDip Buying & Long-Term Growth Stock Strategies - newser.com
Will Roivant Sciences Ltd. (87S) stock outperform benchmarksTrade Signal Summary & Daily Oversold Stock Bounce Ideas - newser.com
Is Roivant Sciences Ltd. (87S) stock a contrarian opportunityMarket Performance Report & Low Drawdown Investment Ideas - nchmf.gov.vn
Is a relief rally coming for Roivant Sciences Ltd. holders2025 AllTime Highs & Verified Momentum Stock Alerts - newser.com
Is Roivant Sciences Ltd. (87S) stock cheap by valuation metrics2025 Dividend Review & Real-Time Market Trend Scan - newser.com
Combining machine learning predictions for Roivant Sciences Ltd.July 2025 Weekly Recap & Technical Analysis for Trade Confirmation - newser.com
What sentiment indicators say about Roivant Sciences Ltd. stockJuly 2025 Retail & AI Forecasted Entry and Exit Points - newser.com
This Red-Hot Biopharma Stock Could Fizzle Out Soon - MSN
Can you recover from losses in Roivant Sciences Ltd.Earnings Overview Report & Precise Trade Entry Recommendations - newser.com
(ROIV) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Top chart patterns to watch in Roivant Sciences Ltd.Quarterly Market Summary & Verified Swing Trading Watchlist - newser.com
Roivant Sciences Ltd. (ROIV) Investor Outlook: Analyzing The 16% Potential Upside - DirectorsTalk Interviews
Using Ichimoku Cloud for Roivant Sciences Ltd. technicals2025 Trade Ideas & Weekly Setup with ROI Potential - newser.com
How sentiment analysis helps forecast Roivant Sciences Ltd.2025 Sector Review & Fast Moving Stock Watchlists - newser.com
Will Roivant Sciences Ltd. continue its uptrendJuly 2025 WrapUp & Daily Entry Point Trade Alerts - newser.com
Will Roivant Sciences Ltd. stock gain from government policiesDay Trade & Daily Technical Stock Forecast Reports - newser.com
Is Roivant Sciences Ltd. stock in correction or buying zoneMarket Activity Recap & AI Driven Price Predictions - nchmf.gov.vn
Roivant Sciences president Venker sells $14.5m in shares By Investing.com - Investing.com Nigeria
Roivant Sciences president Venker sells $14.5m in shares - Investing.com
Roivant Sciences Hits New 52-Week High of $17.12, Up 60.59% - Markets Mojo
Roivant Sciences stock hits all-time high at 16.8 USD By Investing.com - Investing.com South Africa
Roivant Sciences stock hits all-time high at 16.8 USD - Investing.com India
Can Roivant Sciences Ltd. stock deliver consistent earnings growth2025 Key Lessons & Weekly High Potential Stock Alerts - newser.com
Why retail investors pile into Roivant Sciences Ltd. stockQuarterly Growth Report & Stepwise Trade Signal Guides - newser.com
Roivant Sciences president Venker sells $2m in shares By Investing.com - Investing.com Australia
Roivant Sciences president Venker sells $2m in shares - Investing.com
Positive Phase 3 Data and Analyst Support Could Be a Game Changer for Roivant Sciences (ROIV) - Sahm
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Roivant Sciences Ltd Stock (ROIV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
Oct 16 '25 |
Option Exercise |
15.85 |
318,282 |
5,044,770 |
1,823,241 |
| Venker Eric | President & Immunovant CEO |
Oct 17 '25 |
Option Exercise |
15.85 |
118,418 |
1,876,925 |
1,623,377 |
| Venker Eric | President & Immunovant CEO |
Oct 15 '25 |
Sale |
16.93 |
414,683 |
7,020,583 |
1,504,959 |
| Venker Eric | President & Immunovant CEO |
Oct 16 '25 |
Sale |
17.05 |
318,282 |
5,426,708 |
1,504,959 |
| Venker Eric | President & Immunovant CEO |
Oct 17 '25 |
Sale |
17.06 |
118,418 |
2,020,211 |
1,504,959 |
2.07%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):